Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of ErbB, has determined clinical benefit for women affected by metastatic or early stage HER2-positive breast cancer and never previously treated with trastuzumab. Trastuzumab is generally used as first-line treatment of HER2+ metastatic breast cancer and is currently administered beyond progression even without clear evidence supporting such clinical practice. In fact, HER2-positive metastatic breast cancer has a high risk of progressing after first-line therapy, and second-line treatments vary. The aim of the study was to investigate by a systematic review the efficacy of trastuzumab-based treatments beyond progression in HER2-positive metastatic breast cancer.
Materials and methods
We performed a systematic review using Medline, Embase and Cochrane Library data bases and publications in principal meetings or congresses of oncology in Europe and America until September 2008. The main selection criterium was the reporting of time to progression, calculated from the start of each trastuzumab-based therapy to the date of progressive disease or death.
Results
Twelve studies were selected that included a total of 516 patients. The weighted mean time to progression was 23.66 weeks (standard deviation, 4.37) and the median was 26 weeks (range, 13–39). Interestingly, combined trastuzumab plus vinorelbine treatment showed a lower mean and median time to progression (20.59 and 19.57 weeks, respectively), whereas trastuzumab plus capecitabine yielded a mean time to progression of 30.33 weeks.
Conclusions
The added value of the present study has been to provide a quantitative summary measure of time to progression which can be used for comparisons between current and future available regimens.
CainfroccaM., GoldsteinL.J.: Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9: 606–616, 2004.
5.
MontemurroF., DonadioM., ClavarezzaM., RedanaS., JacomuzziM.E., ValabregaG., DaneseS., Vietti-RamusG., DurandoA., VenturiniM., AgliettaM.: Outcome of patients with HER2–positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318–324, 2006.
6.
SlamonD.J., ClarkG.M., WongS.G., LevinW.J., UllrichA., McGuireW.L.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177–182, 1987.
7.
GullickW.J., LoveS.B., WrightC., BarnesD.M., GustersonB., HarrisA.L., AltmanD.G.: C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer, 63: 434–438, 1991.
National Institute for Clinical Excellence (NICE): 2002 Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer, London, England: NICE (Technology Appraisal Guidance no. 34).
10.
ClementsD.M., HollandP.A.: Metastatic disease of the breast and local recurrence of breast cancer. Surgery, 25: 276–279, 2007.
11.
National Institute for Clinical Excellence (NICE).2001Guidance on the Use of Taxanes for the Treatment of Breast Cancer, London, England: NICE (Technology Appraisal Guidance no. 30).
CobleighM.A., VogelC.L., TripathyD., RobertN.J., SchollS., FehrenbacherL., WolterJ.M., PatonV., ShakS., LiebermanG., SlamonD.J.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17: 2639–48, 1999.
15.
LiberatiA., AltmanD.G., TetzlaffJ., MulrowC., GotzscheP.C., IoannidisJ.P.A., ClarkeM., DevereauxP.J., KleijnenJ., MoherD.: The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ital J Public Health, 6(4): 94–126, 2009.
16.
FountzilasG., RazisE., TsavdaridisD., KarinaM., LabropoulosS., ChristodoulouC., MavroudisD., GogasH., GeorgouliasV., SkarlosD.: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 4: 120–125, 2003.
17.
SuzukiY., TokudaY., SaitoY., OhtaM., TajimaT.: Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol, 33: 514–517, 2003.
18.
GelmonK.A., MackeyJ., VermaS., GertlerS.Z., BangemannN., KlimoP., SchneeweissA., BremerK., SoulieresD., TonkinK., BellR., HeinrichB., GrenierD., DiasR.: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer, 5: 52–58, 2004.
19.
García-SáenzJ.A., MartínM., PuenteJ., López-TarruellaS., CasadoA., MorenoF., GrandeE., Díaz-RubioE.: Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer, 6: 325–329, 2005.
20.
BartschR., WenzelC., HussianD., PluschnigU., SeveldaU., KoestlerW., AltorjaiG., LockerG.J., MaderR., ZielinskiC.C., StegerG.G.: Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer, 6: 63, 2006.
21.
AdamoV., FranchinaT., AdamoB., FerraroG., RosselloR., Maugeri SaccàM., ScibiliaC., ValerioM.R., RussoA.: Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol, 18(Suppl 6): vi11–15, 2007.
22.
BartschR., WenzelC., AltorjaiG., PluschnigU., RudasM., MaderR.M., GnantM., ZielinskiC.C., StegerG.G.: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol, 25: 3853–3858, 2007.
23.
MontemurroF., VialeG., DonadioM., BottiniA., BottiG., dei TosA.P., DaneseS., ClavarezzaM., SapinoA., AgliettaM.: Retrospective evaluation of clinical outcomes in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib. Breast Cancer Res Treat, 106(Suppl 1): S185 (abstr 4057), 2007.
24.
BartschR., WenzelC., GampenriederS.P., PluschnigU., AltorjaiG., RudasM., MaderR.M., DubskyP., RottenfusserA., GnantM., ZielinskiC.C., StegerG.G.: Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol, 62: 903–910, 2008.
25.
CancelloG., MontagnaE., D'AgostinoD., GiulianoM., GiordanoA., Di LorenzoG., PlaitanoM., De PlacidoS., De LaurentiisM.: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res, 10: R60, 2008.
26.
FabiA., MetroG., FerrettiG., GiannarelliD., Di CosimoS., PapaldoP., MottoleseM., CarliniP., FeliciA., RussilloM., CognettiF.: Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast, 17: 499–505, 2008.
27.
TokajukP., Czartoryska-ArlukowiczB., WojtukiewiczM.Z.: Continuation of trastuzumab-based therapy beyond disease progression in metastatic breast cancer patients — a retrospective one center analysis. Eur J Cancer, 7(Suppl 6): 221, (abstr 581) 2008.
28.
von MinckwitzG., du BoisA., SchmidtM., MaassN., CuferT., de JonghF.E., MaartenseE., ZielinskiC., KaufmannM., BauerW., BaumannK.H., ClemensM.R., DuerrR., UleerC., AnderssonM., SteinR.C., NekljudovaV., LoiblS.: Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: A German Breast Group 26/Breast International Group 03–05 Study. J Clin Oncol, 27: 1999–2006, 2009.
29.
Von MinckwitzG., ZielinskiC., MaarteenseE., VogelP., SchmidtM., EidtmannH., CuferT., de JonghF.E., KaufmannM., LoiblS.: Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). J Clin Oncol, 26: (abstr 1025), 2008.
30.
MontemurroF., DonadioM., ClavarezzaM., RedanaS., JacomuzziM.E., ValabregaG., DaneseS., Vietti-RamusG., DurandoA., VenturiniM., AgliettaM.: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318–324, 2006.
31.
MontemurroF., RedanaS., NolèF., DonadioM., JacomuzzziM.E., ValabregaG., VialeG., SapinoA., AgliettaM.: Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer, 8: 209, 2008.
32.
RosselloR., AdamoB., FranchinaT., GaripoliC., IorfidaM., FestaV., MontaltoE., ValerioM.R., RussoA., AdamoV.: Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer (MBC): a five-year experience. Ann Oncol, 18(Suppl 11): xi37–xi55 (abstr C26), 2007.
GeyerC.E., ForsterJ., LindquistD., ChanS., RomieuC.G., PienkowskiT., Jagiello-GruszfeldA., CrownJ., ChanA., KaufmanB., SkarlosD., CamponeM., DavidsonN., BergerM., OlivaC., RubinS.D., SteinS., CameronD.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–4273, 2006.
35.
O'ShaughnessyJ., BlackwellK.L., BursteinH., StornioloA.M., SledgeG., BaselgaJ., KoehlerM., LaabsS., FloranceA., RoychowdhuryD.: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressingon trastuzumab therapy. Proc Am Soc Clin Oncol, 26: 1015, 2008.
36.
La TorreG., ChiaradiaG., MannocciA., de WaureC., RicciardiW., CapriS., BamfiF., BianchiC., Lapinet-VeraJ., MaroccoA., PatarnelloF., RecchiaG.: Health Technology Assessment of the anti-HPV vaccination. Ital J Public Health, 4(2)(Suppl 1): 1–60, 2009.
